References
Corless CL et al. (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825
Debiec-Rychter M et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–695
Heinrich MC et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349
Verweij J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127–1134
Heinrich M et al. (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status [abstract]. ASCO Annual Meeting Proceedings. 24: 520S–520S
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Christopher Corless and Michael Heinrich have received research support from and are consultants for Novartis and Pfizer, and are also members of the Speaker's Bureau for Novartis.
Rights and permissions
About this article
Cite this article
Heinrich, M., Corless, C. Does tumor mutational status correlate with clinical response to imatinib?. Nat Rev Clin Oncol 3, 600–601 (2006). https://doi.org/10.1038/ncponc0639
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0639
- Springer Nature Limited
This article is cited by
-
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
British Journal of Cancer (2008)